Toronto Raptors coach Nick Nurse thought his team was flat from the beginning which cost them against the fast-paced Hornets.
Toronto Raptors coach Nick Nurse thought his team was flat from the beginning which cost them against the fast-paced Hornets.
The Board of Directors of Cryptology Asset Group p.l.c. (ISIN: MT0001770107; Ticker: CAP) today resolved to increase the share capital of the Company by 128,375 new shares and to sell 31,625 treasury shares which is the entire position Cryptology holds of own shares after the buyback done over the last months. Shareholders' subscription rights to the new shares and the treasury shares are excluded.
Dancers in hotpants at a military event have sparked a heated debate about women, sex and power.
The "Global Healthcare API Market (2020-2025) by Service, Deployment Model, End user, Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The "Glamping Market Size, Share & Trends Analysis Report by Accommodation Type (Cabins & Pods, Tents, Yurts, Treehouses), by Age Group (18 - 32 Years, 33 - 50 Years), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
[225+ Pages Research Report] According to the recent research report; the global Surgical Sponge Market in 2019 was approximately USD 2,000 Million. The market is expected to surge at a CAGR of 3.5% and is anticipated to surpass USD 2,500 Million by 2026. Top market players in the market are ASC, Zhende Medical, Medtronic, Medicom, Molnlycke, Texpol, BSN medical, Dukal, Medline, Kettenbach, Cardinal Health, Crosstex and others.New York, NY, April 15, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Surgical Sponge Market By Type (X-Ray Detectable Sponges, Cotton Gauze Sponges, Laparotomy Sponges, Nonwoven Sponges, and Others), By Material Type (Cotton, Cellulose, PVA, Polyurethane, Rayon, and Others), By Shape Type (Round, Cylindrical, Square, Rectangle, and Others), By Sterility Type (Sterile Surgical Sponge and Non-Sterile Surgical Sponge), By Sales Channel (Online and Offline), By Application (General Surgery, Neurosurgery, Laparotomy, Dental Surgery, ENT Surgery, and Others), By End-User (Pharmacy, Hospital, Ambulatory Surgery Center, Clinic, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026”. “According to the research report, the global Surgical Sponge Market was estimated at USD 2,000 Million in 2019 and is expected to reach USD 2,500 Million by 2026. The global Surgical Sponge Market is expected to grow at a compound annual growth rate (CAGR) of 3.5% from 2019 to 2026”. Surgical Sponge Market: Overview and Definition A surgical sponge is cotton material inserted during an invasive operation to absorb fluids or separate tissue, with the aim of extracting the absorbent material until the procedure is completed. Gauze sponges are widely used in medicine and surgery as disposable medical supplies. They are usually made of gauze and are used to contain blood and other bodily fluids as well as clean wounds. Surgical sponges are what they're called when they're used in surgery. A surgical sponge is a type of sponge or pad that is used during surgery. A surgical sponge, also known as a lap sponge, is used to collect liquids from a surgical site. It may be used with suction to hold a surgical site clean, by a surgeon trying to stop bleeding, and in a variety of other situations. Request Your Free Sample Report of Surgical Sponge Market @ https://www.fnfresearch.com/sample/surgical-sponge-market (The free sample of this report is readily available on request). Our Free Sample Report Includes: 2020 Updated Report Introduction, Overview, and In-depth industry analysisCOVID-19 Pandemic Outbreak Impact Analysis Included190+ Pages Research Report (Inclusion of Updated Research)Provide Chapter-wise guidance on Request2020 Updated Regional Analysis with Graphical Representation of Size, Share & TrendsIncludes Updated List of table & figuresUpdated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue AnalysisFacts and Factors research methodology (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Key Questions Answered in this Report 1) What were the pre and post-business impacts of COVID-19 on the Surgical Sponge Market? 2) What is the market size, share of the Surgical Sponge Market? 3) Who are the top market players in Surgical Sponge Market? 4) What will be the future market of the Surgical Sponge Market? Key Offerings: Market Size & Forecast by Revenue | 2020−2026Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunitiesMarket Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geographyCompetitive Landscape – Top key vendors and other prominent vendors Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/surgical-sponge-market (You may enquire a report quote OR available discount offers to our sales team before purchase.) Surgical Sponge Market: Industry Major Market Players MedtronicMcKessonMolnlyckeZhende MedicalBSN MedicalWinner MedicalDukal, MedlineJianErKangCardinal HealthHakuzoHartmannTexpol,DeroyalLohmann & RauscherAllmed MedicalAhlstromASCMedicomOwens & MinorCrosstexB. BraunKettenbach To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/surgical-sponge-market Incidences of abdominal diseases such as colon cancer and others are on the rise, which will boost the demand for surgical sponges. Every year, about 96,830 new cases of colon cancer are registered in the United States, according to the American Cancer Society (ACS). During the forecast period of 2013 to 2019, the surgical sponge market is expected to expand at a rapid pace. This rapid expansion can be due to the growing number of surgical procedures performed around the world. In 2010, approximately 7.4 Million stomach surgeries were completed in the United States, Japan, Germany, Spain, the United Kingdom, France, and Italy, with this figure projected to rise to nearly 8,109,000 by 2020. Similarly, the growing geriatric population would boost the demand for surgical sponges, as elderly people are more likely to suffer from abdominal disorders that necessitate surgery. According to the World Health Organization (WHO), the geriatric population would number about 2 billion people by the year 2050. As a result, both of the above variables will certainly improve the demand for laparotomy sponges. Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/surgical-sponge-market Based on type segmentation, the surgical sponge market is divided into x-ray detectable sponges, cotton gauze sponges, laparotomy sponges, nonwoven sponges, and others. The cotton sponges are expected to hold the maximum market share owing to their high fluid absorbency. On the basis of shape type, the market is bifurcated into round, cylindrical, square, rectangle, and others. The rectangle-shaped surgical sponge is widely used in surgeries as they are small and can be easily held in the hands. Based on the sterility type, the market is split into sterile surgical sponges and non-sterile surgical sponges. The non-sterile surgical sponges are widely used by hospitals and clinics as they are more cost-effective compared with sterile surgical sponges, providing good cushioning support to any cuts or wounds. Based on the sterility type, the market is split into sterile surgical sponges and non-sterile surgical sponges. The non-sterile surgical sponges are widely used by hospitals and clinics as they are more cost-effective compared with sterile surgical sponges, providing good cushioning support to any cuts or wounds. The end-user segment is divided into pharmacy, hospital, ambulatory surgery center, clinic, and others. The hospital segment is considered to be the leading segment as a major count of surgeries of various types are operated at big hospitals owing to its big infrastructural and advanced medical facilities. In 2016, North America was the market's top sales contributor, accounting for more than 35% of overall revenue. The growing geriatric population, rising prevalence of abdominal disorders, and increasing number of abdominal surgeries are all contributing to the market's expansion. In Asian countries, the incidence of cesarean section births is also high. Due to a large geriatric population, growing prevalence of abdominal disorders, and increased awareness of laparotomy, this regional market has high growth potential. During the forecast period, Asia Pacific is predicted to have the highest CAGR. Japan, Korea, and China are among the 10 countries with the highest rates of stomach cancer, according to World Cancer Research's annual index. Request Customized Copy of Report @ https://www.fnfresearch.com/customization/surgical-sponge-market (We customize your report according to your research need. Ask our sales team for report customization.) Stryker revealed in June 2016 that over 180 million SurgiCount Protection Sponges have been used in over 10 million surgeries in the United States over the previous five years. SurgiCount's successful implementation in nearly 500 hospitals around the country showed the different hospitals can make inpatient safety protocols. ProCell Surgical Inc. announced the launch of ProCell in June 2020, a proprietary, first-to-market medical system that essentially automates the manual and obsolete method of surgical sponge-blood recovery for intraoperative autotransfusion (IAT). Scientists created microscopic sponges that absorbed and neutralized coronavirus in June 2020. Johnson & Johnson's Ethicon company and Takeda Pharmaceutical decided in April 2020 to cancel the J&J unit's proposed USD 400 million purchase of Takeda's surgical bleeding patch. A Federal Trade Commission inquiry into the proposed agreement based on the possible lack of competition in the market for fibrin sealant patches, which contributed to the decision. Stryker launched a surgical protection company in September 2017 with a no-mistakes sponge device. The machine relied on sterile bar-coded sponges and a computer tablet with proprietary software to keep track of all sponges. The machine boasted zero sponge use after nearly 11 million surgical operations over the last five years, involving the use of more than 200 million sponges. Browse the full “Surgical Sponge Market By Type (X-Ray Detectable Sponges, Cotton Gauze Sponges, Laparotomy Sponges, Nonwoven Sponges, and Others), By Material Type (Cotton, Cellulose, PVA, Polyurethane, Rayon, and Others), By Shape Type (Round, Cylindrical, Square, Rectangle, and Others), By Sterility Type (Sterile Surgical Sponge and Non-Sterile Surgical Sponge), By Sales Channel (Online and Offline), By Application (General Surgery, Neurosurgery, Laparotomy, Dental Surgery, ENT Surgery, and Others), By End-User (Pharmacy, Hospital, Ambulatory Surgery Center, Clinic, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/surgical-sponge-market This report segments the surgical sponge market as follows: Global Surgical Sponge Market: By Type Segmentation Analysis Cotton Gauze SpongesNonwoven SpongesX-Ray Detectable SpongesLaparotomy SpongesOthers Global Surgical Sponge Market: By Material Type Segmentation Analysis PolyurethaneCottonCellulosePVARayonOthers Global Surgical Sponge Market: By Shape Type Segmentation Analysis CylindricalRoundRectangleSquareOthers Global Surgical Sponge Market: By Sterility Type Segmentation Analysis Non-Sterile Surgical SpongeSterile Surgical Sponge Global Surgical Sponge Market: By Sales Channel Segmentation Analysis OfflineOnline Global Surgical Sponge Market: By Segmentation Analysis Application General SurgeryDental SurgeryLaparotomyNeurosurgeryENT SurgeryOthers Global Surgical Sponge Market: By End-User Segmentation Analysis PharmacyHospitalAmbulatory Surgery CenterClinicOthers Related Reports: Healthcare in IT Market: https://www.fnfresearch.com/healthcare-in-it-market Digital Pathology Market: https://www.fnfresearch.com/digital-pathology-market Digital Health Market: https://www.fnfresearch.com/digital-health-market Sleeping Aids Market: https://www.fnfresearch.com/sleeping-aids-market Absorbable Heart Stent Market: https://www.fnfresearch.com/absorbable-heart-stent-market About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch Follow Us Twitter: https://twitter.com/fnfresearch Contact Us: Facts & Factors USA: +1-347-989-3985 Email: firstname.lastname@example.org Web: https://www.fnfresearch.com Blog: http://fnfnewsblog.com
TEHRAN, Iran — Iran has finalized a deal with Russia to purchase 60 million doses of Sputnik V coronavirus vaccine. The state-run IRNA news agency reported Thursday that Iran’s ambassador to Russia, Kazem Jalali, says the contract for enough vaccines to inoculate 30 million people was “signed and finalized.” Jalali says Iran will receive the vaccines by the end of the year. Iran began a 10-day lockdown Saturday amid a fourth wave of coronavirus infections. Authorities ordered most shops closed and offices restricted to one-third capacity in cities declared as “red zones,” with the highest infection rates. Over 85% of the country is either a red or orange zone. Only some 200,000 doses have been administered in the country of 84 million, according to the World Health Organization. COVAX, an international collaboration to deliver the vaccine equitably across the world, delivered its first shipment to Iran on Monday from the Netherlands, containing 700,000 AstraZeneca doses. Earlier this year, Iran started its vaccine program with a limited number of Russian Sputnik V vaccine doses going to medical workers. ___ THE VIRUS OUTBREAK: — WHO: Europe surpasses 1 million COVID-19 deaths — India skyrockets past 14M virus cases; 200,000 new infections in 1 day — French families decry toll of pandemic as nation nears 100,000 deaths — Bangkok nightlife clusters expose Thailand’s virus stumbles ___ Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine ___ HERE’S WHAT ELSE IS HAPPENING: NEW DELHI — India’s two largest cities have imposed stringent restrictions on movement and one planned to use hotels and banquet halls to treat coronavirus patients. New Delhi announced stay-at-home orders for the weekend. The moves in the capital came after similar measures were imposed in the financial capital of Mumbai. Those moves came as daily infections in the country shot past 200,000 Thursday amid a devastating surge that is straining a fragile health system. The soaring cases and deaths have forced India to delay exports of vaccines to other countries. “The surge is alarming,” says S.K. Sarin, a government health expert in New Delhi. Arvind Kejriwal, Delhi’s top elected official, says despite rise in infections, 5,000 hospital beds are still available in the capital and added capacity. Still, more than a dozen hotels and wedding banquet halls were ordered to convert into COVID-19 centres where doctors from nearby hospitals will treat the moderately ill. ___ GENEVA — U.S. Secretary of State Antony Blinken has kicked off an appeal to other countries to help inject $2 billion more to the U.N.-backed program to ship coronavirus vaccines to the world’s poorest countries. The United States is co-hosting a pledging and donor conference Thursday, bringing together four presidents, three prime ministers and other dignitaries to help buttress the $6.3 billion already raised for the U.N.-backed COVAX program. Blinken laid out a goal to raise COVAX’s target of vaccinating 20% of populations in the affected countries to 30%, with the addition of $2 billion in funds. The COVAX effort has been providing millions of vaccine doses to 92 of the world’s poorest countries. “We recognize that as long as COVID is spreading and replicating anywhere, it poses a threat to people everywhere,” Blinken says. Donors were expected to chip in either funds — prime minister Stefan Lofven announced Sweden was increasing its contribution to COVAX from $20 million to $280 million — or announce plans to share doses with the low- and middle-income countries. Blinken highlighted the Biden administration’s contribution of $2 billion to COVAX in March and its plans to add another $2 billion through 2022. ___ DHAKA, Bangladesh — The death toll from coronavirus in Bangladesh crossed 10,000 on Thursday. The country’s health facilities are struggling to cope with the increased demands for hospital beds for the critical patients. There were more than 4,000 confirmed cases and 94 deaths reported in the last day. Officials say new strains of the virus were spreading quickly, prompting the government to enforce a nationwide lockdown. They say the number of daily cases has increased seven-fold in a month while the number of deaths has doubled in recent weeks. Dr. A.S.M. Alamgir, principal scientific officer of the government’s Institute of Epidemiology, Disease Control and Research, told The Associated Press the deaths could worsen in coming weeks. Authorities say Bangladesh, a nation of more than 160 million people, has only 825 Intensive Care Unit beds for the critical patients in both government and private hospitals. Total cases have increased to more than 707,000 and more than 10,000 confirmed deaths, according to the Ministry of Health Affairs. ___ BERLIN — The head of Germany’s disease control agency has warned that the situation in some of the country’s hospitals is “dramatic” in the need for treatment for COVID-19. The Robert Koch Instiute reported 29,425 confirmed coronavirus cases in the past day and 293 deaths. Lothar Wieler, who heads the Robert Koch Institute, says clinics in some cities and counties have already run out of intensive care beds. He says many of those requiring treatment are young adults. Germany has recorded nearly 3.1 million cases of the coronavirus and nearly 80,000 confirmed deaths. ___ BUDAPEST — A Hungarian minister dismissed concerns over the effectiveness of a Chinese-produced COVID-19 vaccine Thursday, claiming it provided better protection from coronavirus than some Western shots without providing any evidence. Gergely Gulyas, chief of staff to Hungarian Prime Minister Viktor Orban, told an online press briefing that all six vaccines currently in use in Hungary are “reliable and effective,” and there is no need to provide a third dose of a jab produced by Chinese state-owned company Sinopharm. Hungary is the only country in the European Union to have approved the Sinopharm vaccine and has already received more than 1 million of the 5 million doses it ordered. Prime Minister Viktor Orban received the first of the two-dose shot in February, saying he trusted it the most. But the distributor in the United Arab Emirates began offering a third dose of the vaccine to a small number of people in March, saying it had not produced enough protective antibodies in some cases. Concerns over the effectiveness of the vaccine were further heightened on the weekend when China’s top disease control official said current vaccines offer low protection against the coronavirus. Gao Fu later told The Associated Press that his words had been misinterpreted, and he was speaking about the effectiveness rates for “vaccines in the world, not particularly for China.” ___ GENEVA — A top official from the World Health Organization says Europe has surpassed 1 million deaths from COVID-19. Dr. Hans Kluge says the situation remains “serious” with about 1.6 million new cases reported each week in the 53 countries that make up its European region. Addressing recent concerns about vaccines, Kluge says the risk of people suffering blood clots is far higher for people with COVID-19 than people who receive AstraZeneca’s coronavirus vaccine. Kluge pointed to “early signs that transmission may be slowing across several countries” and cited “declining incidence” among the oldest people. He says the proportion of COVID-19 deaths among people over 80, who have been prioritized for vaccines, had dropped to nearly 30%. Worldwide, a tally by Johns Hopkins University shows nearly 3 million deaths have been linked to COVID-19 — with the Americas hardest hit, followed by Europe. The United States, Brazil and Mexico have reported the highest number of deaths, collectively, at more than 1.1 million. ___ TOKYO — Japan’s western metropolis of Osaka reported a record 1,208 new coronavirus cases. Tokyo reported a two-month high of 729 daily cases. A virus alert status began in Tokyo on Monday, allowing the authorities to issue binding orders for shorter hours at bars and restaurants. Osaka and four other prefectures are also on alert, and the government is expected to add a few more areas for the elevated measures Friday. The rapid resurgence in Japan comes less than three months before the Olympics. On Thursday, a top ruling party official suggested an option of cancelling the Olympics if the infections make it impossible. Officials are concerned that the sense of urgency is not shared by the people. Experts on a Tokyo metropolitan government taskforce warned that the new variant could replace the conventional coronavirus virus and trigger more infections by early May. Dr. Shigeru Omi, head of a government taskforce, urged municipal leaders to take action quickly to curb the spread of the infections. Tokyo Gov. Yuriko Koike urged the residents to take maximum protection and asked non-Tokyo residents, except for essential workers, not to visit the area. She also asked the people to avoid travelling during the upcoming “Golden week” holidays beginning at the end of April. Overall, Japan added 4,300 new cases Wednesday for a total of about half a million and 9,500 confirmed deaths. ___ BELGRADE, Serbia — Serbia has announced it will begin packing and later producing Russia’s Sputnik V coronavirus vaccine, which would make it the first European state outside Russia and Belarus to begin manufacturing the jab. Serbian President Aleksandar Vucic on Thursday visited an institute in the Serbian capital, Belgrade, where he said the Russian vaccine will be manufactured in a “few months.” He said for now, the vaccine will be packed in Belgrade after receiving its components from Russia. Although the European Union drug regulator, EMA, has not yet approved Sputnik V, the vaccine has been registered for use in dozens of countries worldwide. Serbia has one of the highest inoculation rates in Europe, mainly thanks to the government’s large purchases of the Sinopharm vaccine from China and the Sputnik V vaccine. The country also is administering the vaccines developed by Pfizer-BioNTech and Oxford-AstraZeneca. Serbia also plans to start producing the Sinopharm vaccine. ___ PARIS — France is expected Thursday to pass the grim milestone of 100,000 COVID-19 deaths, after a year of hospital tensions, on-and-off lockdowns and personal loss that have left families nationwide grieving the pandemic’s unending, devastating toll. The country of 67 million will be the eighth in the world to reach the symbolic mark, and the third in Europe after the United Kingdom and Italy. The cumulative death toll since the start of the epidemic totalled 99,777 on Wednesday evening. In recent days, French health authorities have been reporting about 300 new daily deaths from COVID-19. Lionel Petitpas, president of the association “Victims of COVID-19,” told the Associated Press that the number of 100,000 deaths is “an important threshold.” After months of people getting accustomed to the virus, the figure “is piercing a lot of minds. It is a figure we thought would never be reached,” he said. France plunged into a third, partial lockdown at the beginning of April, as new infections were surging and hospitals getting close to saturation. An overnight nationwide curfew has been in place since mid-December, and all France’s restaurants, bars, gyms, cinemas and museums have been closed since October. ___ HONG KONG — Hong Kong is expanding its vaccination drive to include residents below 30 as it sought to boost the city’s slower-than-expected uptake of COVID-19 vaccines. Residents between 16 and 29 will be able to register to get inoculated beginning April 23, according to Secretary for the Civil Service Patrick Nip. The expansion of the vaccination program comes amid widespread hesitancy among residents towards getting inoculated and a deepening mistrust in its government, following the deaths of several chronically ill patients after they received the vaccines as well as reports of residents getting the wrong jab. As of Wednesday, only about 8.4% of residents in the city of 7.5 million have received vaccines. Hong Kong began administering COVID-19 vaccines to residents starting in late February, and its vaccination rate has lagged behind countries like Singapore, which started vaccinating just a week before Hong Kong but has since achieved a nearly 20% vaccination rate. Currently, Hong Kong is offering residents the choice of the Chinese-made Sinovac vaccine and the Pfizer vaccine, known as BioNTech in the city. ___ NAIROBI, Kenya —The Africa CDC director says he hopes India will lift export restrictions on COVID-19 vaccines as soon as possible, warning that “India is not an island.” John Nkengasong spoke as the African continent of 1.3 billion people doesn’t know when second doses of key vaccines will arrive and India sees a resurgence in infections. The country is a major vaccine producer and a critical supplier to the U.N.-backed COVAX initiative that aims to bring shots to some of the world’s poorest countries. “If you finish vaccinating your people before Africa or other parts of the world, you have not done yourself any justice because variants will emerge and undermine your own vaccination efforts,“ Nkengasong said. He said the uncertainty around the arrival of second doses puts the African continent in a “very dicey situation.” African officials aim to vaccinate 750 million people over the next two years but just under 14 million vaccine doses have been administered across the 54 countries. ___ BANGKOK, Thailand — Thailand’s coronavirus cases surpassed 1,500 on Thursday to set another record, sparking concerns the country's outbreak may spiral out of hand. More than 8,000 cases have been recorded since April 1 in a fresh outbreak linked to nightclubs and bars in central Bangkok. The 1,543 new cases pushes the country’s tally to 37,543, with 97 deaths. Dr. Chawetsan Namwat from the Department of Disease Control said the outbreak appeared to have spread beyond entertainment venues with new cases now linked to seminars, office meetings and student field trips. He said the National Infection Control Committee will meet later Thursday to discuss new measures. Up to 6,000 hospital beds will be added in Bangkok. Mass travel for the Thai new year holiday this week is fueling the surge, said Dr. Opas Karnkavinpong, director-general of the Disease Control Department. More worrying is that infections include a more contagious variant of the virus first found in the U.K. The outbreak as added pressure on the government to speed up its slow vaccination drive, which has seen less than 1% of its population inoculated. ___ The Associated Press
DUBAI, United Arab Emirates — The Middle East's largest operator of malls expects revenue and earnings to climb back to pre-pandemic levels by the end of next year and is moving full steam ahead with plans to develop its biggest mall ever. In a wide-ranging interview with The Associated Press on Thursday, Majid Al Futtaim CEO Alain Bejjani said business is steadily rebounding amid vaccine rollouts in some countries of the region, kicking 2021 off to a relatively strong start. “We’re not out of the woods across the markets, but things are improving,” Bejjani said. “Going back to the pre-pandemic levels— to 2019 level— in my opinion, will happen by the end of 2022 in terms of financial results." The company's plethora of retail and leisure holdings include the iconic Mall of the Emirates in Dubai, hundreds of VOX cinema screens and more than 350 Carrefour grocery stores in the Middle East and beyond. Named after its Emirati billionaire founder, the company's largest markets are the United Arab Emirates, Saudi Arabia and Egypt, but its reach extends as far as Pakistan, Kenya and Uzbekistan. The company's projections of a rebound and its plans for expansion reflect the faster than anticipated recovery of Middle East economies from the coronavirus pandemic, though uneven vaccine distribution remains a concern. Majid Al Futtaim, which employs some 43,000 people regionally, saw its revenue plummet by 7% to $8.9 billion last year and earnings drop by 19% to around $1 billion due to coronavirus lockdowns and restrictions. The hardest-hit side of the business was its leisure and entertainment arm, where revenue fell by 49% to $380 million and earnings plummeted by 122%, resulting in losses of $25 million. Despite last year's slump, Majid Al Futtaim plans to unveil 30 new movie theatre screens this year in Saudi Arabia, is developing it’s biggest mall project ever in Riyadh, and is opening what will be the largest mall in Oman at the end of 2021. “Every country has had their own set of challenges to deal with. The reality is the fastest recovery is the UAE... and we expect very fast recoveries in other markets like Saudi Arabia,” Bejjani said. “We have also seen Egypt being very resilient.” The United Arab Emirates has rapidly rolled out COVID-19 vaccines, which are free of charge for citizens and residents. Saudi Arabia is also expanding its vaccination rollout and has offered all residents free coronavirus treatment since the start of the pandemic. It's not back to business as usual just yet, though. Majid Al Futtaim— like many businesses globally— is having to adjust to new realities, including the potential imposition of so-called “digital passports." In Bahrain, for example, where Majid Al Futtaim operates 30 cinema screens, only people who've been vaccinated or recently recovered from COVID-19 will be allowed into cinemas, gyms and other select spaces soon. Bejjani said the company is “very supportive of any measure” that gives customers the feeling of being safe. “Whenever there is an additional regulation, that actually gives people even more certainty, I think this is a plus, whether it is the vaccine passport, whether it is something else,” he said. “At the end of the day, what’s important is that people want to go back to normal. People want to go back to consumption.” The company's rapid growth and expansion since its inception in 1992 mirrors that of its home base of Dubai, where a frenetic construction boom has transformed it from a fishing village into one of the most talked about modern cities in the world. The company's economic rebound is also closely tied to that of Dubai's, where the International Monetary Fund expects the country's overall economy to grow this year by 3.2%. At the height of the pandemic last year, Dubai imposed a 24-hour curfew and government-mandated permits were needed to leave the house. Even then, Majid Al Futtaim's Carrefour supermarkets remained busy. Because the United Arab Emirates imports most of its produce, meat and poultry, Majid Al Futtaim’s policy of stockpiling a three months’ supply of basic goods proved crucial when nervous shoppers in Dubai rushed to stock up on goods during the first days of growing restrictions on movement. In the wake of 2020, Bejjani said the company is in conversation with the government of the UAE to increase stockpiles of certain products up to six months. The company is also working with 6,000 local farmers to increase production of fruits and vegetables, while also supporting farmers as far away as Kenya to ensure a diversified supply of fresh food for its UAE stores. A half dozen Carrefours in the UAE began growing their own lettuce and herbs in hydroponic farms last year, Bejjani said. The company's Carrefour business across the region saw earnings grow by 14% to $440 million last year, even as revenue slightly fell. That was due in part to the company's overall 188% increase in online sales as people moved toward grocery delivery services. By the end of last year, the company also saw more visitors returning to its malls and cinemas. Majid Al Futtaim’s crown jewel in Dubai is the Mall of the Emirates, home to an indoor ski slope and the world’s busiest Carrefour supermarket. A recent walk through the mall showed it's cafes, restaurants and stores teeming with visitors. Still, there were also many shuttered storefronts - evidence of the economic slowdown that had hit Arab Gulf oil exporting nations even before the pandemic. The region's many sprawling luxury malls aren't just for shopping, though. They offer an escape for millions of people seeking respite from the long summer months. Bejjani said despite some store closures across its malls, there continues to be “big demand” in the Gulf for more entertainment and retail spaces. Aya Batrawy, The Associated Press
Presenter Charlene White revealed the plans during Thursday’s episode of the daytime show.
RedTeam ranks 350 on the list and was one of only 500 companies to be honoredORLANDO, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- RedTeam, a rapidly-growing construction management platform for commercial contractors, has earned a spot on the Financial Times’ new Americas’ Fastest Growing Companies list, a ranking of high-growth companies throughout the Americas. RedTeam placed 350 out of 500 companies to earn a place on the prestigious list. Companies were judged on their compound annual growth rate in revenue between 2016 and 2019. “As the construction industry continues to look for innovative solutions to solve decades-old problems, our growth is driven by our success in delivering a best-in-class digital platform,” said Frédéric Guitton, RedTeam’s chief strategy officer. “We’re constantly innovating to allow people to collaborate from any location at any time and make sure all team members have the information they need to perform their work accurately, confidently and safely.” In addition to the America’s Fastest Growing Companies list, RedTeam also earned a spot on the Inc. 5000 list of the nation’s fastest-growing private companies. More than 20,000 projects were created in RedTeam in 2020, with more than 350,000 team members collaborating and contributing to the projects. RedTeam is constantly adding tools and functions to meet the needs of the construction industry. RedTeam is now offering Fieldlens by RedTeam, a mobile plan markup tool that allows contractors to document conversations, punch list items, manage RFIs and submittals, update projects and more using photos and video and pin those directly to project plans. The company also made enhancements to its TeamPlayer app, which facilitates subcontractor collaboration by making it easier for all team members to access and respond to critical documents and transactions, resulting in more efficient communication, reduced risk, greater accountability, increased compliance and an overall improved subcontract relationship. For more information on RedTeam, visit www.redteam.com. About RedTeam SoftwareRedTeam Software offers the most comprehensive cloud-based solution for construction project and accounting management. With intuitive social design interface and real-time updates, RedTeam enables construction and accounting teams to collaborate effectively online at all stages of a project - from business development and pre-construction to closeout. Press ContactMatt GreenfieldUproar PR for RedTeammgreenfield@uproarpr.com 321-236-0102 x 234
Helen Whitelaw appeared on Tipping Point before Motor Neurone Disease rendered her speechless.
Olivia Munn, Ken Jeong, Winston Duke and more stars teamed up to shed light on the history of anti-Asian violence in America in a new PSA.
Top-scoring striker Calvert-Lewin remains unavailable due to an abductor problem.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce it is hosting a Corporate Update webinar, on Thursday, April 15th at 1 pm ET that will provide investors with an update on the Company's recent business developments. Registration Link: https://us02web.zoom.us/webinar/register/WN_pRyhGijjSgCGKKsE90lMPQ Specifically, the webinar will feature Medivolve CEO Doug Sommerville as he provides an overview on the Company's recent developments, including March sales numbers and new testing services that are being offered. Representatives from the maker of the AditxtScore COVID-19 immunity test will also join the webinar to share more details on their innovative technology. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics. About Medivolve Inc. Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) focuses on commercializing technologies to help combat the COVID-19 pandemic. This includes providing convenient and accessible medical services for testing. Medivolve is comprised of a team of renowned global medical and business advisors that have developed a proprietary strategy to capitalize on high-margin opportunities across three areas: the prevention, detection, and treatment of COVID-19. This panel includes prominent Stanford neurologist and immunologist Dr. Lawrence Steinman as well as Dr. Glenn Copeland, one of North America’s most prominent orthopedic treatment and sports medicine specialists. About Collection Sites, LLC Collection Sites, LLC is a wholly-owned subsidiary of Medivolve, Inc. The company provides pop-up COVID-19 lab testing services, business-focused testing services, and at-home testing services, powered by CLIA-licensed laboratories. Please visit www.testbeforeyougo.com for more information. For additional information, please contact: Doug Sommerville, CEO Doug.Sommerville@medivolve.ca For investing inquiries please contact: email@example.com For US media enquires please contact: Veronica Welch firstname.lastname@example.org Cautionary Note Regarding Forward-looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to sales results; the proposed roll-out of business testing; the Company’s expansion into telehealth; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Coverage of Prince Philip's death sparked 109,741 complaints.
Forecasts by Technology (Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), by Application (Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Diseases, Microbiology, Others), by Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (USA, Canada) PLUS Analysis of Leading MDx Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North American Molecular Diagnostics (MDx) Market Report 2021-2031" - https://www.reportlinker.com/p06061839/?utm_source=GNW Growing Prevalence of Infectious Diseases Anticipated to Augur Market GrowthAccording to the CDC, in the U.S., hospital-acquired infections (HAI) account for over 1.5 million infections & nearly 95,000 associated deaths per year. Molecular diagnostic is critical in the field of infectious disease testing as it provides rapid & successful results. The rising prevalence of infectious diseases & hospital-acquired infections is therefore expected to fuel molecular diagnostics market across the North American region from 2021 to 2031.Which Factors are Fueling North America Molecular Diagnostics Market Growth?- Growing Geriatric Population Base- Increase in Demand for Point-of-Care Facilities- Growing Prevalence of Target Diseases Such as Genetic, CVDs, and Neurological Diseases- Introduction of Technologically Advanced ProductsWhich Factors are Restraining Growth?- High Prices of Molecular Diagnostics Tests- Presence of Ambiguous Regulatory Framework to Impede Market GrowthTechnological Advancements to Boost Market GrowthAccording to the analysis, advancements in technology is projected to boost North American molecular diagnostics industry growth as they provide greater accuracy and are cost-effective. The market is likely to be guided by the launch of MinION, an affordable and compact sequencer that supplies users in small peripheral laboratories and point of care facilities. Also, high demand for over-the-counter diagnostics is expected to help drive market growth in this area. Furthermore, some of the key factors such as advanced cancer diagnostic testing coupled with growing demand for genetic testing is expected to fuel market growth further through 2031.UNIQUE COVID-19 VARIATIONS- only available in this report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy.How do prominent players strengthen their position throughout the world?You must read this newly updated report if you are involved in this sector. The report shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.Discover how to stay aheadOur 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall North American market and country level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing North America Molecular Diagnostics Market. See how to exploit the opportunities.Forecasts to 2031 and other analyses reveal the commercial prospects. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.. You find original analyses, with business outlooks and developments.. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments.Discover sales predictions for the North American market and submarketsTechnology. Polymerase Chain Reaction- Multiplex PCR- Other PCR. In Situ Hybridization. Isothermal Nucleic Acid Amplification Technology. Chips and Microarrays. Mass Spectrometry. Sequencing. Transcription Mediated Amplification. OthersApplication. Oncology- Breast Cancer- Prostate Cancer- Colorectal Cancer- Cervical Cancer- Kidney Cancer- Liver Cancer- Blood Cancer- Lung Cancer- Other Cancer. Pharmacogenomics. Infectious Diseases- Methicillin-Resistant Staphylococcus Aureus- Clostridium Difficile- Vancomycin-Resistant Enterococci- Carbapenem-Resistant Bacteria- Flu- Respiratory Syncytial Virus- Candida- Tuberculosis and Drug-Resistant TBA- Meningitis- Gastrointestinal Panel Testing- Chlamydia- Gonorrhea- HIV- Hepatitis C- Hepatitis B- Other Infectious Diseases. Genetic Testing- Newborn Screening- Predictive and Presymptomatic Testing- Other Genetic Testing. Neurological Disease. Cardiovascular Diseases. Microbiology. OthersProduct. Instruments. ReagentsTest Location. Point-of-Care. Over the Counter. Central LaboratoriesIn addition to the revenue predictions for the overall North American market and segments, you will also find revenue forecasts for country by segments as well:. U.S. Molecular Diagnostics Market- Revenue Forecasts by Technology- Revenue Forecasts by Application- Revenue Forecasts by Product- Revenue Forecasts by Test Location. Canada Molecular Diagnostics Market- Revenue Forecasts by Technology- Revenue Forecasts by Application- Revenue Forecasts by Product- Revenue Forecasts by Test LocationLeading companies and the potential for market growthOverall revenue for North America molecular diagnostics market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the North America Molecular Diagnostics Market. Some of the companies profiled in this report include are Roche Diagnostics, Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Dako (Agilent Technologies), Danaher, FOUNDATION MEDICINE, INC., Genomic Health (Exact Sciences Corporation), Hologic, Inc., Illumina, Inc., HTG Molecular Diagnostics, Inc., Grifols, S.A., QIAGEN, Siemens Healthcare GmbH, and Sysmex Corporation.Key Questions Answered by this Report:. What is the current size of the North America Molecular Diagnostics market? How much will this market be worth from 2021 to 2031?. What are the main drivers and restraints that will shape the North America Molecular Diagnostics market over the next ten years?. What are the main segments within the North America Molecular Diagnostics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?. What factors will affect that industry and market over the next ten years?. What are the largest national markets for the North America Molecular Diagnostics? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?. How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?. Which are the leading companies and what are their activities, results, developments, and prospects?. What are the main trends that will affect the North America Molecular Diagnostics market between 2021 and 2031?. What are the main strengths, weaknesses, opportunities, and threats for the market?. How will the North America Molecular Diagnostics market evolve over the forecasted period, 2021 to 2031?. How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.Information found nowhere elseWith our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.This study is intended for everybody needing commercial analyses for the North America Molecular Diagnostics Market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06061839/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
In a joint letter sent to the International Football Association Board (IFAB), which determines the laws of the game, FIFPRO and the PFA said existing trials using permanent concussion substitutes should be extended to test parallel temporary concussion replacements "as soon as possible".
Trump supporters called Ivanka a ‘disappointment’ for getting the jab
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Manus Bio, Inc. (Manus Bio), a leading US manufacturer of sustainable natural ingredients, announced today the launch of NutraSweet Natural™, a plant-based sweetener with zero calories and 100% pure tasting sweetness to enjoy in daily life. Manus Bio is paving the way for next-generation calorie reduction with a unique green technology for sourcing nature’s sweetest ingredients while minimizing its environmental footprint. Despite their initial appeal, traditional alternative sweeteners have typically been associated with an unpalatable aftertaste, making them an imperfect alternative to sugar. With this hurdle in mind, NutraSweet Natural™ was created by isolating only the sweetest, purest parts of the stevia leaf and incorporating them into a proprietary blend to create the taste of sugar without the calories. The result is a revolutionary natural sweetener with a clean “just-like-sugar” taste with none of the guilt or aftertaste of traditional alternative sweeteners. “Consumers today are prioritizing health, wellness, and sustainability and are increasingly demanding better, tastier, and healthier options for the foods and ingredients that they consume. According to the Centers for Disease Control and Prevention, a staggering 49% of all Americans have tried to lose weight in the past year. We are proud to be able to offer a unique next-generation zero-calorie sweetener that allows us to indulge in sweetness while maintaining lifestyle goals,” said Brendan Naulty, President of Sweeteners & Natural Ingredients at Manus Bio. Heather Barbarino, VP of Marketing and Communications, added, “NutraSweet™ is an American brand that has delivered sweetness to consumers for decades. We are thrilled to re-introduce the brand with the launch of NutraSweet Natural™. It revolutionizes sweetness to offer consumers a healthy alternative with a natural great taste. As a critical part of NutraSweet Natural™, its unprecedented taste profile was designed with deep respect, empathy, and appreciation for nature. Simply put, we’re Keeping Nature Natural, NutraSweet Natural™ is both good for you and good for the planet.” Be among the first to taste NutraSweet Natural™ sweetener with a 70-count box of sachets available for purchase at www.nutrasweetnatural.com. About Manus Bio:Manus Bio leverages rapid advances in biology to produce complex natural ingredients used in our daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural products. Using its proprietary fermentation technology, Manus Bio recreates advanced natural processes for next-generation biomanufacturing and provides sustainable and cost-effective sources of ingredients for health, wellness, and nutrition. To learn more, visit www.manusbio.com. CONTACT: Contact: Heather Barbarino, VP of Marketing and Communications E-mail: firstname.lastname@example.org
In March, “Novaturas” Group resumed flights from Lithuania, Latvia and Estonia to Tenerife and Egypt. From Vilnius airport plains took off to United Arab Emirates and Maldives. During March, the Company served 6.4 thousand customers – 18% more than in the corresponding period last year. If compared to 2019, the number of customers served in March 2021 reached half the number of customers served in 2019. In total, during January - March, the Company served 8.9 thousand customers - 71% less than last year and 78% less than in 2019. Group revenue in March amounted to EUR 4.1 million and was 6% lower than the same time last year and 59% lower than in 2019. Cumulative January - March turnover reached EUR 5.5 million and was 76% and 81% lower than the corresponding time last year and in 2019. "March 2021 has been noted by two positive aspects - we have finished refunding our travelers for the trips that have been cancelled due to the pandemic, and we have served 18% more customers than during same month last year. If compared revenues we have generated this March and in March 2019, we are only 6% behind. These achieved results might look modest if compared with operational and financial results generated in 2019, but in today's context it is a big step forward towards more sustainable planning”, says Audronė Keinytė, Head of “Novaturas” Group. In April, the Company have resumed flights from all the Baltics to the most popular summer holiday destination - Turkey. The first plane took off from Vilnius on the 1st of April – the earliest of all the Baltics. Flights from Tallinn have started on the 3d of April, and plains from Riga will take off on the 21st of April. Winter holiday programs to Egyptian resorts and Tenerife are also continued in April. Flights to other popular summer destination Greece is planned to start in May if the epidemiological situation is in favor. About “Novaturas” Group AB “Novaturas” Group is the largest tour operator in the Baltic States, offering summer and winter package holidays in more than 30 destinations worldwide and more than 100 sightseeing routes. In 2019, the group served more than 293 thousand customers. CFOTomas Staškūnas email@example.com, +370 687 10426
Equities in Canada’s largest market rose at the open on Thursday, as gold prices jumped on the back ...